

## Joint Working

### Executive Summary

<b>Project title</b>	Leicestershire Primary Care Cardiovascular Hubs
<b>Project partners</b>	Cross Counties: C/o Kibworth Medical Centre, Smeeton Road, Kibworth, LE8 0LG  North Blaby: C/o Enderby Medical Centre, Shortridge Lane, Leicester, LE19 4LY  Daiichi Sankyo UK Ltd
<b>Start date</b>	March 2021 – August 2022
<b>Project support</b>	Daiichi Sankyo UK Ltd direct contribution - £130,320 NHS Cross Counties indirect contribution of £116,100

### Project summary

This project is to assess patients presenting with Cardiovascular Symptoms including newly diagnosed patients across LLR (Leicester, Leicestershire and Rutland) CCG who are currently assessed by a GP but in most cases referred onwards to secondary care for assessment and further testing. The cardiovascular (CVD) Hubs will ensure the management stays within primary care and more importantly aligns with NHSE vision to optimize cardiovascular care and bring care closer to home for patients.

The patients will be assessed at the CVD hub by clinical pharmacists supported by consultant cardiologist in line with the NHS long term plan of upskilling and educating pharmacist. The groups of patients who would be reviewed within CVD hubs will include the management of historic CVD/CVA (stroke) patients, post MI and CVA care and other CVD conditions with complexities. The consultant pharmacist will run audit matrix to identify patients for virtual reviews for optimisation of atrial care and heart failure care. These patients will be referred to the CVD hub where the clinical pharmacist will assess these patients as well as newly diagnosed CVD patients. Consultant cardiologist will run one clinic per week for CVD complex care, referral by pharmacist team, pre-existing and newly diagnosed patients with CVD.

This is an 18 month project and thereafter NHS aims to offer CVD hubs across Leicestershire primary care.

## **Expected benefits to patients and the NHS & Daiichi Sankyo UK Ltd**

### Expected benefits for the Patient:

- Prevention and reduction in risk of developing further complications associated with cardiovascular disease
- Improve patient experience and Quality of life
- Where possible during Covid and any other pandemic the hub will access the risk and benefits of accessing patient referral to hospital.
- Quality disease review and management.
- Ability to make informed decisions about their healthcare and take accountability.

### Expected benefits for NHS:

- Maintain clinical excellence and high-quality care for patients.
- Provide more timely access to care.
- Enhance patient care, access to existing NHS services and support financial stability in the primary care setting.
- Creating Supporting Infrastructure – Make sure service providers know what is expected and who will help them deliver that.
- Maintain financial control and achieve agreed activity levels.
- Make a real difference to patient care through influencing the culture of the NHS. We particularly want to 'mainstream' the use of this initiative across the NHS within the fabric of NHS clinical services and support the NHS Long Term Plan.

### Expected benefits for Daiichi Sankyo UK:

- Support the legacy effect in management of long-term conditions within the NHS
- Working with NHS partners to implement delivery of the NHS long term plan and GP contract as well as help support and deliver compassionate care.
- Showcase collaborative partnership with NHS and innovation for desirable outcome measures including journal publication and associated publicity likely resulting in future collaborations and subsequent raise in profile of Daiichi Sankyo UK Ltd.
- Create more opportunities for the appropriate use of Direct Oral Anticoagulants, including Daiichi Sankyo UK's medicines in suitable patients in line with local treatment guidelines. If this improvement occurs, we are likely to see an increase in DOAC prescriptions.
- Raising the profile of Daiichi Sankyo UK Ltd as an NHS Partner of choice in improving patient outcomes